Purdue OxyContin Contaminant Testing Inadequate, FDA Warning Letter Says
Executive Summary
FDA is objecting to Purdue Pharma's process for detecting contaminants in OxyContin in a GMP warning letter on contamination of the opiate analgesic
You may also be interested in...
Purdue OxyContin Marketing Strategy To Be Topic Of GAO Investigation
Purdue Pharma's marketing strategies for OxyContin will be the topic of a Government Accounting Office report requested by House Appropriations/Commerce, Justice, State & Judiciary Subcommittee Chairman Frank Wolf (R-Va.)
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials